Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.

Xiao Jun Wang,Yi-Ho Wang,Shing Chau Tony Li,Christina Gkitzia,Soon Thye Lim,Liang Piu Koh,Francesca Lorraine Wei Inng Lim,William Hwang

Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.

2021

Xiao Jun Wang
Yi-Ho Wang
Shing Chau Tony Li
Christina Gkitzia
Soon Thye Lim
Liang Piu Koh
Francesca Lorraine Wei Inng Lim
William Hwang

Patients experiencing relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have limited treatment options and poor prognosis. Tisagenlecleucel (TIS) has shown improved clinical outcomes...

Keywords:

adult patients
Internal medicine
Refractory Diffuse Large B-Cell Lymphoma
private insurance
cost effectiveness
Oncology
Lymphoma
Diffuse large B-cell lymphoma
Refractory
budget impact
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations